

◆ Department of Continuing Medical Education ◆

Conflict of Interest Disclosure and Resolution & Core Competencies
Multidisciplinary Approaches to Cancer Symposium
November 7-9, 2024

City of Hope takes responsibility for the content, quality, and scientific integrity of this CME activity.

City of Hope is accredited by the Accreditation Council for Continuing Medical Education (ACCME). As a fully accredited ACCME Category 1 CME credit provider, the Continuing Medical Education Department has in place policies and procedures which insure the balance, independence, objectivity and scientific rigor in all of its educational activities. City of Hope complies with the [Standards for Integrity and Independence in Accredited Continuing Education](#) of the (ACCME), which REQUIRE that all relevant disclosed conflicts of interest be mitigated prior to the educational activity.

To this end all faculty presenters who are in a position to control the content of an educational activity must identify any real or apparent conflict(s) of interest by disclosing to the Department of CME all relevant financial relationships¹ with any ineligible company². To comply with more intense scrutiny by accreditation agencies, should you disclose any relevant conflict of interest with an ineligible company, the content of your presentation must be peer reviewed prior to presenting. Presentations will be provided to participants as an e-syllabus or in a meeting handout, all relevant disclosures will be made known to participants prior to the start of the activity.

In furtherance of program impartiality, we request the use of generic drug names in your presentation as opposed to trade names. Under no circumstances will we accept trade names. Additionally, contents of your presentation must be based solely on scientific methods generally accepted by the medical community. Data will have been objectively selected from peer-reviewed literature and will be presented in an unbiased manner.

CORE COMPETENCIES

The American Board of Medical Specialties (ABMS) and the Accreditation Council of Graduate Medical Education (ACGME) have embarked on a joint initiative to quantify and evaluate a set of 6 physician core competencies by which the individual physician will be measured for Residency Certification, Board Certification and more recently, Maintenance of Certification (MOC). Individual hospitals and other health care delivery organizations will now also be evaluated by the Joint Commission on Accreditation of Healthcare Organizations (JCAHO) on their practice and demonstration of the 6 core competencies.

In brief, the actual term “core competencies” refers to those six abilities (competencies) that are central (core) to the practice of medicine, specifically: (1) Practice-Based Learning and Improvement, (2) Patient Care, (3) Systems-Based Practice, (4) Medical Knowledge, (5) Interpersonal and Communication Skills, and (6) Professionalism. To assist our conferees in demonstrating their completion of CME in the six core competencies, the educational content of each presentation will be noted by numbers 1-6 in the table below. CME certificates for this activity will reflect those core competencies addressed by the educational content of the overall conference.

Conference Faculty	Commercial Interest	Conflict/ Resolution & Faculty Discussion of Off-Label Drugs	Core Competencies
Haris Ali, MD	Consultant for GSK, Karyopharm, PharmaEssentia, & Sobi; Grant/Research Support from Incyte	The educational content has been peer-reviewed, an attestation on file and no conflicts were noted. <i>Off-label/Investigational use of: BTK Degraders, Epcoritamab, Sonrotoclax</i>	1, 2, 3, 4, 5 & 6
Arya Amini, MD	Consultant for AstraZeneca; Grant/Research Support from Genentech, RefleXion, Regeneron & Varian	The educational content has been peer-reviewed, an attestation on file and no conflicts were noted.	1 Moderator Planner
John Baird, MD	Grant/Research Support from Cargo Therapeutics, Genentech-Roche, Kite Pharma-Gilead, Janssen & Regeneron Pharmaceuticals; On the Speakers Bureau for Kite Pharma-Gilead	The educational content has been peer-reviewed, an attestation on file and no conflicts were noted.	1, 2, 3 & 4
Linda D. Bosserman, MD, PhD	I do not have any relevant financial relationships with any ineligible companies.	None	1, 2, 3, 4, 5 & 6
Alan H. Bryce, MD	Grant/Research Support from Astellas, AstraZeneca, Bayer, Johnson & Johnson, Lantheus, Merck, Myovant, & Pfizer	The educational content has been peer-reviewed, an attestation on file and no conflicts were noted. <i>Off-label/Investigational use of: Fludarabine, Melphalan, Hypomethylating Agents, Selinexor, INCA 33989, Janssen Vaccine, Imetalstat</i>	2 & 4

Conference Faculty	Commercial Interest	Conflict/ Resolution & Faculty Discussion of Off-Label Drugs	Core Competencies
Antoine Lyonel Carre, MD, MPH	I do not have any relevant financial relationships with any ineligible companies.	None	1, 2, 3 & 4
Dani Ran Castillo, MD	I do not have any relevant financial relationships with any ineligible companies.	None	1, 2, 3, 4, 5 & 6
Savita V. Dandapani, MD, PhD	Grant/Research Support from Imaginab	The educational content has been peer-reviewed, an attestation on file and no conflicts were noted. <i>Off-label/Investigational use of: Teclistamab, Talquetamab, Ide-Cel, Cilta-Cel, Elranatamab, Mezigdomide, Iberdomide</i>	1, 2, 3, 4, 5 & 6
Loretta Erhunmwunsee, MD	Consultant for AstraZeneca; Grant/Research Support from AstraZeneca, National Cancer Institute, Lung Cancer Research Foundation, & American Association of Thoracic Surgeons; and Other Financial/Material Interest from Bristol Myers Squibb	The educational content has been peer-reviewed, an attestation on file and no conflicts were noted.	2 & 4
Marwan G. Fakih, MD	Consultant for AstraZeneca, Bayer, Bristol Myers Squibb, Delcath, Essai, GlaxoSmithKline, Merck, Pfizer, Roche/Genentech, Sanofi, & Taiho Oncology; and Grant/Research Support from Agenus Bio, Bayer, Genentech, & Verastem	The educational content has been peer-reviewed, an attestation on file and no conflicts were noted.	1 & 4
Scott Glaser, MD	I do not have any relevant financial relationships with any ineligible companies.	None	1, 2, 3, 4, 5 & 6
Scott R. Goldsmith, MD	Consultant for Bristol Myers Squibb, Janssen & Sanofi; and On the Speakers Bureau for Bristol Myers Squibb & Janssen	The educational content has been peer-reviewed, an attestation on file and no conflicts were noted.	1, 2 & 4
Ernest S. Han, MD, PhD	Grant/Research Support from Bayer, and ImaginAb	The educational content has been peer-reviewed, an attestation on file and no conflicts were noted.	1, 2, 3 & 4
Murali Janakiram, MD, MS	Consultant for Bristol Myers Squibb, Janssen, & Legend Biotech; and Grant/Research Support from Bristol Myers Squibb, Janssen, & Fate Therapeutics	The educational content has been peer-reviewed, an attestation on file and no conflicts were noted.	1, 2 & 4
Irene Kang, MD	Consultant for Caris Life Sciences, Daiichi Sankyo, Gilead & Pfizer	The educational content has been peer-reviewed, an attestation on file and no conflicts were noted.	1, 2, 3 & 4
Jonathan Kessler, MD	Consultant for Boston Scientific & Ethicon	The educational content has been peer-reviewed, an attestation on file and no conflicts were noted.	1, 2, 3 & 4 Planner
Edward S. Kim, MD, MBA	Consultant for Mirati Therapeutics, Avllino, GlaxoSmithKline, & Roche	The educational content has been peer-reviewed, an attestation on file and no conflicts were noted.	1, 2, 3, 4, 5 & 6
Clayton Lau, MD	I do not have any relevant financial relationships with any ineligible companies.	None	1, 2, 3, 4, 5 & 6
Richard T. Lee, MD	I do not have any relevant financial relationships with any ineligible companies.	None	2 & 4

Conference Faculty	Commercial Interest	Conflict/ Resolution & Faculty Discussion of Off-Label Drugs	Core Competencies
Daneng Li, MD	Consultant for Abbvie, Adagene, AstraZeneca, Coherus, Eisai, Exelixis, Genentech, Merck, Sumitomo Pharma; and Grant/Research Support from AstraZeneca	The educational content has been peer-reviewed, an attestation on file and no conflicts were noted.	4 Moderator Reviewer Planner
Heather McGee, MD, PhD	I do not have any relevant financial relationships with any ineligible companies.	None	1, 2, 3, 4 & 6
Badri Modi, MD	Consultant for Merck; On the Speakers Bureau for Regeneron	The educational content has been peer-reviewed, an attestation on file and no conflicts were noted.	1, 2 & 4
Charles B. Nguyen, MD	I do not have any relevant financial relationships with any ineligible companies.	None	1, 2, 3 & 4
Amy Plemons, BSN, RN	I do not have any relevant financial relationships with any ineligible companies.	None	Moderator Planner
Mustafa Raoof, MD, MS	Grant/Research Support from Exact Sciences and Reger, Inc.	The educational content has been peer-reviewed, an attestation on file and no conflicts were noted.	2 & 4 Moderator Planner
Tulio E. Rodriguez, MD	On the Speakers Bureau for Sanofi	The educational content has been peer-reviewed, an attestation on file and no conflicts were noted.	1 & 2
Crystal Saavedra, BA	I do not have any relevant financial relationships with any ineligible companies.	None	Planner
Tanya Siddiqi, MD	Consultant for Abbvie, AstraZeneca, BeiGene, Bristol Myers Squibb, & Gilead; On the Speakers Bureau AstraZeneca, BeiGene & Bristol Myers Squibb; and Other Financial/Material Interests from BeiGene	The educational content has been peer-reviewed, an attestation on file and no conflicts were noted. <i>Off-label/Investigational use of: Botensilimab, Balstilimab</i>	1, 2, 3, 4, 5 & 6 Planner Moderator
Joo Song, MD	I do not have any relevant financial relationships with any ineligible companies.	None	1 & 4 Moderator Planner
Mihae Song, MD	I do not have any relevant financial relationships with any ineligible companies.	None	1, 2, 3, 4, 5 & 6
Swetha Kambhampati Thiruvengadam, MD	Consultant for Abbvie & Ipsen; Grant/Research Support from ADC-Therapeutics, Genmab, Genentech & Ipsen	The educational content has been peer-reviewed, an attestation on file and no conflicts were noted.	1, 2 & 4
Cristian Tomasetti, PhD	Consultant for Bayer; and Royalties from Exact Sciences; and Scientific Advisor for PronomiQ Inc.	The educational content has been peer-reviewed, an attestation on file and no conflicts were noted.	4
Jennifer Tseng, MD	Grant/Research Support from Intuitive Surgical	The educational content has been peer-reviewed, an attestation on file and no conflicts were noted.	1, 2, 3 & 4
Christina Yeon, MD	I do not have any relevant financial relationships with any ineligible companies.	None	1, 2, 3, 4, 5 & 6 Moderator Planner

1. The ACCME defines “relevant” financial relationships” as financial relationships with an ineligible company (in any amount), occurring within the past 24 months, that create a conflict of interest.
2. The ACCME defines an “ineligible company” as any entity producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.